Xenetic Biosciences, Inc. (XBIO)
NASDAQ: XBIO · Real-Time Price · USD
2.600
+0.030 (1.17%)
At close: Nov 14, 2025, 4:00 PM EST
2.610
+0.010 (0.38%)
After-hours: Nov 14, 2025, 5:49 PM EST

Xenetic Biosciences Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 20202015 - 2019
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2015 - 2019
Net Income
-3.16-3.96-4.13-6.55-5.65-10.89
Upgrade
Depreciation & Amortization
---0.030.040.03
Upgrade
Asset Writedown & Restructuring Costs
---1.79-9.24
Upgrade
Stock-Based Compensation
0.080.170.280.510.410.47
Upgrade
Other Operating Activities
------3.06
Upgrade
Change in Accounts Payable
0.10.08-0.26-0.350.46-0.38
Upgrade
Change in Other Net Operating Assets
0.260.890-0.0800.33
Upgrade
Operating Cash Flow
-2.72-2.82-4.11-4.65-4.74-4.27
Upgrade
Sale (Purchase) of Intangibles
----0.5--
Upgrade
Investing Cash Flow
----0.5--
Upgrade
Issuance of Common Stock
----11.455.43
Upgrade
Financing Cash Flow
----11.455.43
Upgrade
Net Cash Flow
-2.72-2.82-4.11-5.156.721.16
Upgrade
Free Cash Flow
-2.72-2.82-4.11-4.65-4.74-4.27
Upgrade
Free Cash Flow Margin
-95.07%-112.69%-161.98%-272.23%-408.21%-976.60%
Upgrade
Free Cash Flow Per Share
-1.76-1.83-2.69-3.27-4.61-6.67
Upgrade
Levered Free Cash Flow
-2.55-2.19-2.85-4.56-2.29-3.07
Upgrade
Unlevered Free Cash Flow
-2.55-2.19-2.85-4.56-2.29-3.07
Upgrade
Change in Working Capital
0.360.97-0.26-0.430.46-0.05
Upgrade
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q